Results 161 to 170 of about 77,176 (263)

Potential cost-effectiveness of outdoor unhealthy food and drink advertising restrictions in Western Australia. [PDF]

Public Health Nutr
Ananthapavan J, Angeles MR, Groves E, Brown V, Backholer K, Sacks G, Sartori A.   +6 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Monetary savings and neuropsychological functioning in older adults without dementia. [PDF]

Neuropsychology
Molinare CP, Noriega-Makarskyy DT, Williams JT, Oyen E, Kim P, Axelrod J, Han SD.   +6 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Prediction of Relapse Using Digital Technology in People in Recovery From Substance Use Disorders: Early Economic Evaluation With a Case Study of the Subreal App. [PDF]

JMIR Form Res
Bouttell J, Bartler M, Bolton S.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Gi4SaveLife: a community-led model for sustainable voluntary blood donation in rural Sierra Leone. [PDF]

BMJ Glob Health
Fernandez Turienzo C, November L, Turay M, Kamara P, Lassie RK, Kamara JS, Kamara MK, Kamara M, Duraman M, Kuhrt K, Leather AJM, Gevao S, Williams PT.   +12 more
europepmc   +1 more source

Physical activity and sedentary behavior surveillance using accelerometers in Japanese urban adults: A descriptive study of participation and adherence. [PDF]

PLoS One
Kitano N, Kawakami R, Fujii Y, Yamaguchi D, Muramatsu Y, Matsushita Y, Mizuno Y, Miyamoto S, Yoshida T, Kai Y, Arao T.   +10 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Component Clinical and Cost Outcomes Complementing Value of Information: Case Study of a Tuberculosis Diagnostics Clinical Trial. [PDF]

Pharmacoeconomics
Pei P, Qoshe L, Florance G, Pandya A, Weinstein MC, Freedberg KA, Paltiel AD, Reddy KP.   +7 more
europepmc   +1 more source